Adage Capital Partners
MSLE

Adage Capital Partners’s Satellos Bioscience MSLE Stock Holding History

Adage Capital Partners’s Portfolio MSLE Stock Details MSLE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.17M Sell
150,000
-230,354
-61% -$1.58M ﹤0.01% 893
2026
Q1 		$2.14M Buy
+380,354
New +$3.74M ﹤0.01% 833

Other funds holding MSLE

Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return

Adage Capital Partners's MSLE Position: Q2 2026 in Review

Adage Capital Partners reduced its Satellos Bioscience (MSLE) stake by 61% in Q2 2026, selling an estimated $1.58M and leaving 150,000 shares worth $1.17M. The position accounts for ﹤0.01% of the portfolio, ranked #893.

Adage Capital Partners first reported a position in MSLE in Q1 2026 and has held it in 2 quarters since. The position peaked at $2.14M in Q1 2026. 26 funds tracked by Wall St. Rank hold MSLE as of Q2 2026.

  • Adage Capital Partners held 150,000 shares of Satellos Bioscience worth $1.17M as of Q2 2026.
  • Adage Capital Partners sold 230,354 Satellos Bioscience shares in Q2 2026, an estimated $1.58M.
  • Satellos Bioscience made up ﹤0.01% of Adage Capital Partners's portfolio in Q2 2026, its #893 holding.
  • Adage Capital Partners first reported a position in Satellos Bioscience in Q1 2026 and has held it in 2 quarters since.
  • Adage Capital Partners's Satellos Bioscience position peaked at $2.14M in Q1 2026.
  • 26 funds tracked by Wall St. Rank held Satellos Bioscience as of Q2 2026.

Based on Adage Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.